{
  "docId": "019de075-2dc4-7413-a6ea-ecd3ab0cc295",
  "docSlug": "e0f48061a961c5e04d59dc15b9a47e3c",
  "documentTitle": "MindMed | Investor Presentation Deck | 36 slides",
  "authorId": "mindmed",
  "authorName": "MindMed",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 36,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "key_takeaways",
  "function": "summarize",
  "density": "dense",
  "nDataPoints": 0,
  "notes": "The slide uses a clear, bulleted list to summarize clinical trial outcomes.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-2dc4-7413-a6ea-ecd3ab0cc295/26",
  "deckHref": "/decks/019de075-2dc4-7413-a6ea-ecd3ab0cc295",
  "deckJsonHref": "/decks/019de075-2dc4-7413-a6ea-ecd3ab0cc295.json",
  "deckAnchorHref": "/decks/019de075-2dc4-7413-a6ea-ecd3ab0cc295#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.128,
        "w": 0.714,
        "x": 0.143,
        "y": 0.198
      },
      "kind": "callout",
      "text": "Phase 1 study results support progression of MM-110 (zolunicant) *",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "403bf5b9-3b95-485f-b609-2084a47d30d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.26,
        "w": 0.85,
        "x": 0.152,
        "y": 0.408
      },
      "kind": "list",
      "text": "Results from Phase 1 clinical trial demonstrate tolerability and support progression of MM-110\nLinear PK maintained across the tested doses and frequencies\nClinical effects align with potent CNS engagement\nQOD regimen aligns with preclinical evidence & offers potential to be a more suitable regimen in opioid withdrawal",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d29c06ec-5f14-4ca5-9cf7-fa1ba24d1e92",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.58,
        "x": 0.057,
        "y": 0.088
      },
      "kind": "paragraph",
      "text": "Results of Phase 1 clinical trial demonstrate tolerability and support progression of MM-110",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "723ee039-5b44-455b-abdd-beb31fd71aef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.04,
        "y": 0.85
      },
      "kind": "source-note",
      "text": "* Continued development of MM-110 is currently subject to the Company obtaining non-dilutive sources of capital and/or collaboration partners.\nPK: Pharmacokinetics; CNS: Central Nervous System; QOD: Latin for \"every other day\" (dosing regimen)",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9e6834c5-f46f-4fb1-98da-652115c39e32",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.04,
        "w": 0.45,
        "x": 0.057,
        "y": 0.037
      },
      "kind": "title",
      "text": "Phase 1 Study Results - Key Takeaways",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "89eadf98-ed9b-46bc-a3d2-32f4ae8ae490",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}